Carvalho, Vinícius Brumon Xavier de

English

Lume 5.8

Evento Salão UFRGS 2022: SIC - XXXIV SALÃO DE INICIAÇÃOCIENTÍFICA DA UFRGSAno 2022Local Campus Centro - UFRGSTítulo Bone marrow mesenchymal cells for adult COVID-19 inmechanical ventilation due to SARS: a safety and feasibilityclinical studyAutor VINICIUS BRUMON XAVIER DE CARVALHOOrientador LUCIA MARIANO DA ROCHA SILLAJustification: Severe Acute Respiratory Syndrome (SARS) due to COVID-19 hascaused millions of deaths. Some previous studies have shown that advanced therapyusing Mesenchymal Stromal Cells (MSC) and its immunomodulatory properties couldbe a potential therapeutic strategy to block pulmonary inflammation. This clinicalstudy was elaborated to evaluate the MSC adoptive immunotherapy as adjuvanttherapy for SARS caused by COVID-19. Objective: The primary endpoint was todefine safety and feasibility of allogeneic bone marrow (BM) MSC immunotherapy inpatients with SARS due to COVID-19. The secondary endpoints were to monitortreatment response by time to SARS resolution according to PaO2/FiO2 ratio (P/Fratio) variations; to verify C-reactive protein (CRP) serum variation and flowcytometric analysis of peripheral blood leukocytes immune profiling of the patients.Methods: BM MSC were obtained from the BM collection bag/filter cellular residuesand expanded ex vivo up to the second passage. Two infusions of 1x10⁶ BM-MCScells/kg were administered between 72 to 96 hours after mechanical ventilation wasstarted. Patients were continuously monitored during the infusion procedure and for30 days after the infusions to evaluate clinical and laboratory changes according topredetermined parameters. Results: Between October 2020 and January 2021,eight patients under invasive mechanical ventilation were enrolled. No adverseevents were associated with the infusion. Six patients (75%) have increasedclinical-laboratory parameters, being cured from SARS by reaching P/F ratio over300 in a median of 5,5 days. Among the responders there was one patient withadvanced liver disease that died of liver failure after ICU discharge. Treatment wasfollowed by a decreased tendency in CRP serum and T lymphocytes increased in theresponders. Conclusion: In view of its safety and feasibility the immunotherapyusing BM-MSC might be considered an alternative to COVID-19 infected patientsdeveloping SARS.

Bone marrow mesenchymal cells for adult COVID-19 in mechanical ventilation due to SARS: a safety and feasibility clinical study

https://lume.ufrgs.br/bitstream/10183/261415/1/Resumo_77781.pdf

Bone marrow mesenchymal cells for adult COVID-19 in mechanical ventilation due to SARS: a safety and feasibility clinical study

Abstract

Similar works

Full text

Available Versions

Lume 5.8